PL2906252T3 - Koniugaty pirolobenzodiazepina-przeciwciało anty-HER2 - Google Patents
Koniugaty pirolobenzodiazepina-przeciwciało anty-HER2Info
- Publication number
- PL2906252T3 PL2906252T3 PL13788691T PL13788691T PL2906252T3 PL 2906252 T3 PL2906252 T3 PL 2906252T3 PL 13788691 T PL13788691 T PL 13788691T PL 13788691 T PL13788691 T PL 13788691T PL 2906252 T3 PL2906252 T3 PL 2906252T3
- Authority
- PL
- Poland
- Prior art keywords
- pyrrolobenzodiazepine
- her2 antibody
- antibody conjugates
- conjugates
- her2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261712924P | 2012-10-12 | 2012-10-12 | |
| US201261712928P | 2012-10-12 | 2012-10-12 | |
| US201361784233P | 2013-03-14 | 2013-03-14 | |
| US201361784270P | 2013-03-14 | 2013-03-14 | |
| US201361784249P | 2013-03-14 | 2013-03-14 | |
| EP13788691.7A EP2906252B1 (en) | 2012-10-12 | 2013-10-11 | Pyrrolobenzodiazepine-anti-her2 antibody conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2906252T3 true PL2906252T3 (pl) | 2017-11-30 |
Family
ID=49552324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13788691T PL2906252T3 (pl) | 2012-10-12 | 2013-10-11 | Koniugaty pirolobenzodiazepina-przeciwciało anty-HER2 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20150273077A1 (enExample) |
| EP (1) | EP2906252B1 (enExample) |
| JP (1) | JP2016502504A (enExample) |
| KR (1) | KR20150083856A (enExample) |
| CN (1) | CN104955485B (enExample) |
| AU (1) | AU2013328621B2 (enExample) |
| BR (1) | BR112015008177A2 (enExample) |
| CA (1) | CA2887896A1 (enExample) |
| CY (1) | CY1119287T1 (enExample) |
| DK (1) | DK2906252T3 (enExample) |
| ES (1) | ES2640449T3 (enExample) |
| HR (1) | HRP20171264T1 (enExample) |
| HU (1) | HUE034505T2 (enExample) |
| LT (1) | LT2906252T (enExample) |
| MX (1) | MX2015004423A (enExample) |
| PL (1) | PL2906252T3 (enExample) |
| PT (1) | PT2906252T (enExample) |
| RS (1) | RS56222B1 (enExample) |
| SI (1) | SI2906252T1 (enExample) |
| SM (1) | SMT201700444T1 (enExample) |
| WO (1) | WO2014057115A1 (enExample) |
| ZA (1) | ZA201502267B (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| MX368648B (es) | 2010-04-15 | 2019-10-09 | Seattle Genetics Inc | Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas. |
| CN103068405A (zh) | 2010-04-15 | 2013-04-24 | 西雅图基因公司 | 靶向吡咯并苯并二氮杂卓结合物 |
| US9399641B2 (en) | 2011-09-20 | 2016-07-26 | Medimmune Limited | Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates |
| CA2850375C (en) | 2011-10-14 | 2019-07-02 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| CA2850264C (en) | 2011-10-14 | 2019-11-05 | Medimmune Limited | Pyrrolobenzodiazepines |
| AU2012322934B2 (en) | 2011-10-14 | 2016-09-08 | Medimmune Limited | Pyrrolobenzodiazepines |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| PT2906248T (pt) | 2012-10-12 | 2019-03-04 | Medimmune Ltd | Pirrolobenzodiazepinas e conjugados das mesmas |
| EP2906249B1 (en) | 2012-10-12 | 2018-06-27 | MedImmune Limited | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
| DK2839860T3 (da) | 2012-10-12 | 2019-06-17 | Medimmune Ltd | Pyrrolobenzodiazepiner og konjugater deraf |
| AU2013366493B2 (en) | 2012-12-21 | 2017-08-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| US9567340B2 (en) | 2012-12-21 | 2017-02-14 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
| MX363787B (es) | 2013-03-13 | 2019-04-03 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de los mismos. |
| KR102066318B1 (ko) | 2013-03-13 | 2020-01-14 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨쥬게이트 |
| GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| EP3193940A1 (en) * | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| SI3191135T1 (sl) | 2014-09-12 | 2021-01-29 | Genentech, Inc. | Anti-HER2 protitelesa in imunokonjugati |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| CA2957148A1 (en) * | 2014-09-17 | 2016-03-24 | Genentech, Inc. | Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines |
| CN107148285B (zh) | 2014-11-25 | 2022-01-04 | Adc治疗股份有限公司 | 吡咯并苯并二氮杂䓬-抗体缀合物 |
| US9504694B2 (en) | 2015-03-19 | 2016-11-29 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
| GB201506394D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201506389D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| CR20180243A (es) | 2015-10-02 | 2018-07-31 | Genentech Inc | Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso |
| US10689458B2 (en) | 2015-11-30 | 2020-06-23 | Pfizer Inc. | Site specific HER2 antibody drug conjugates |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| CN106248971B (zh) * | 2016-08-19 | 2017-10-03 | 合肥瀚科迈博生物技术有限公司 | 用于检测人血清中her2含量的elisa试剂盒、使用方法及用途 |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| GB201619490D0 (en) * | 2016-11-17 | 2017-01-04 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| RS61795B1 (sr) * | 2017-02-08 | 2021-06-30 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin antitela |
| WO2018146199A1 (en) | 2017-02-08 | 2018-08-16 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| SMT202200490T1 (it) | 2017-04-18 | 2023-01-13 | Medimmune Ltd | Coniugati di pirrolobenzodiazepina |
| WO2018193102A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| CA3057744A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-cd25 antibody-drug conjugate |
| KR20200028950A (ko) | 2017-06-14 | 2020-03-17 | 에이디씨 테라퓨틱스 에스에이 | 항-cd25 adc의 투여를 위한 투약량 체제 |
| SI3668874T1 (sl) | 2017-08-18 | 2022-04-29 | Medimmune Limited | Pirolobenzodiazepinski konjugati |
| CA3177215C (en) | 2017-09-29 | 2026-06-09 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| MX2020010110A (es) | 2018-03-28 | 2020-11-06 | Mitsubishi Tanabe Pharma Corp | Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos. |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| US11141490B2 (en) * | 2018-07-13 | 2021-10-12 | Research Foundation Of The City University Of New York | Antibody-drug conjugates based on gold compounds |
| CN113631560B (zh) | 2019-03-15 | 2025-02-18 | 麦迪穆有限责任公司 | 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物 |
| BR112021017616A2 (pt) * | 2019-03-25 | 2021-11-09 | Daiichi Sankyo Co Ltd | Conjugado de derivado de anticorpo anti-her2-pirrolobenzodiazepina |
| GB201908128D0 (en) | 2019-06-07 | 2019-07-24 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| WO2021030358A1 (en) | 2019-08-12 | 2021-02-18 | Regeneron Pharmaceuticals, Inc. | Macrophage stimulating 1 receptor (mst1r) variants and uses thereof |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| AU2023298568A1 (en) | 2022-06-30 | 2025-01-09 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2398975T3 (es) * | 2004-03-01 | 2013-03-25 | Spirogen Sàrl | Derivados de 11-hidroxi-5H-pirrolo[2,1-c][1,4]benzodiazepin-5-ona como intermedios clave para la preparación de pirrolobenzodiazepinas sustituidas en C2 |
| GB0508084D0 (en) * | 2005-04-21 | 2005-06-01 | Spirogen Ltd | Pyrrolobenzodiazepines |
| US20080112961A1 (en) * | 2006-10-09 | 2008-05-15 | Macrogenics, Inc. | Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same |
| GB0819095D0 (en) * | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| WO2010151793A1 (en) * | 2009-06-26 | 2010-12-29 | Five Prime Therapeutics, Inc. | Therapeutic antibody target validation and screening in vivo |
| CN103068405A (zh) * | 2010-04-15 | 2013-04-24 | 西雅图基因公司 | 靶向吡咯并苯并二氮杂卓结合物 |
| PT2528625E (pt) * | 2010-04-15 | 2013-10-17 | Spirogen Sarl | Pirrolobenzodiazepinas e conjugados das mesmas |
| MX368648B (es) * | 2010-04-15 | 2019-10-09 | Seattle Genetics Inc | Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas. |
| US9586996B2 (en) * | 2010-04-30 | 2017-03-07 | Esperance Pharmaceuticals, Inc. | Lytic-peptide-Her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use |
| DK2707031T3 (da) * | 2011-05-08 | 2019-10-07 | Legochem Biosciences Inc | Protein-active agent conjugates and method for preparing the same |
| JP6104257B2 (ja) * | 2011-10-14 | 2017-03-29 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピンおよびそのコンジュゲート |
| WO2013177481A1 (en) * | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
-
2013
- 2013-10-11 PT PT137886917T patent/PT2906252T/pt unknown
- 2013-10-11 LT LTEP13788691.7T patent/LT2906252T/lt unknown
- 2013-10-11 CN CN201380065413.1A patent/CN104955485B/zh not_active Expired - Fee Related
- 2013-10-11 MX MX2015004423A patent/MX2015004423A/es unknown
- 2013-10-11 RS RS20170839A patent/RS56222B1/sr unknown
- 2013-10-11 HU HUE13788691A patent/HUE034505T2/en unknown
- 2013-10-11 HR HRP20171264TT patent/HRP20171264T1/hr unknown
- 2013-10-11 KR KR1020157012365A patent/KR20150083856A/ko not_active Withdrawn
- 2013-10-11 PL PL13788691T patent/PL2906252T3/pl unknown
- 2013-10-11 DK DK13788691.7T patent/DK2906252T3/en active
- 2013-10-11 WO PCT/EP2013/071343 patent/WO2014057115A1/en not_active Ceased
- 2013-10-11 SM SM20170444T patent/SMT201700444T1/it unknown
- 2013-10-11 SI SI201330762T patent/SI2906252T1/sl unknown
- 2013-10-11 CA CA2887896A patent/CA2887896A1/en not_active Abandoned
- 2013-10-11 BR BR112015008177A patent/BR112015008177A2/pt not_active IP Right Cessation
- 2013-10-11 ES ES13788691.7T patent/ES2640449T3/es active Active
- 2013-10-11 EP EP13788691.7A patent/EP2906252B1/en active Active
- 2013-10-11 AU AU2013328621A patent/AU2013328621B2/en not_active Ceased
- 2013-10-11 US US14/434,810 patent/US20150273077A1/en not_active Abandoned
- 2013-10-11 JP JP2015536163A patent/JP2016502504A/ja active Pending
-
2015
- 2015-04-07 ZA ZA2015/02267A patent/ZA201502267B/en unknown
-
2017
- 2017-09-05 CY CY20171100933T patent/CY1119287T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20150273077A1 (en) | 2015-10-01 |
| CN104955485A (zh) | 2015-09-30 |
| BR112015008177A2 (pt) | 2017-09-19 |
| EP2906252A1 (en) | 2015-08-19 |
| SI2906252T1 (sl) | 2017-10-30 |
| JP2016502504A (ja) | 2016-01-28 |
| AU2013328621A1 (en) | 2015-04-23 |
| KR20150083856A (ko) | 2015-07-20 |
| RS56222B1 (sr) | 2017-11-30 |
| CY1119287T1 (el) | 2018-02-14 |
| EP2906252B1 (en) | 2017-06-14 |
| CA2887896A1 (en) | 2014-04-17 |
| CN104955485B (zh) | 2018-01-30 |
| HUE034505T2 (en) | 2018-02-28 |
| SMT201700444T1 (it) | 2017-11-15 |
| MX2015004423A (es) | 2015-10-29 |
| WO2014057115A1 (en) | 2014-04-17 |
| ES2640449T3 (es) | 2017-11-03 |
| HRP20171264T1 (hr) | 2017-10-20 |
| ZA201502267B (en) | 2017-09-27 |
| DK2906252T3 (en) | 2017-09-11 |
| LT2906252T (lt) | 2017-09-11 |
| AU2013328621B2 (en) | 2016-12-01 |
| PT2906252T (pt) | 2017-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2300020I1 (hu) | Pirrolobenzodiazepin-antitest konjugátumok | |
| IL264558A (en) | Anti–il–23p19 antibodies | |
| ZA201502267B (en) | Pyrrolobenzodiazepine-anti-her2 antibody conjugates | |
| PL2906253T3 (pl) | Koniugaty pirolobenzodiazepina-przeciwciało anty-psma | |
| SMT201800010T1 (it) | Coniugati pirrolobenzodiazepina-anticorpo anti-cd22 | |
| ZA201502523B (en) | Pyrrolobenzodiazepine-anitbody conjugates | |
| IL235042A0 (en) | Anti–fcrn antibodies | |
| IL234848A0 (en) | Protease controlled antibodies | |
| IL236259A0 (en) | Anti 15–siglec antibodies | |
| ZA201407316B (en) | Anti-fgfr2 antibody | |
| ZA201407079B (en) | Cdr-modified anti-siglec-15 antibody | |
| GB201220242D0 (en) | Antibody | |
| EP2811018A4 (en) | ANTI-BODY ANTI-sAPPß | |
| IL235188A0 (en) | Antibodies against c-pdgf |